Cargando…
Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing
Sequencing the first human genome in 2003 took 15 years and cost $2.7 billion. Advances in sequencing technologies have since decreased costs to the point where it is now feasible to resequence a whole human genome for $1000 in a single day. These advances have allowed the generation of huge volumes...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891608/ https://www.ncbi.nlm.nih.gov/pubmed/32623783 http://dx.doi.org/10.1111/imcb.12372 |
_version_ | 1783652734376869888 |
---|---|
author | Field, Matt A |
author_facet | Field, Matt A |
author_sort | Field, Matt A |
collection | PubMed |
description | Sequencing the first human genome in 2003 took 15 years and cost $2.7 billion. Advances in sequencing technologies have since decreased costs to the point where it is now feasible to resequence a whole human genome for $1000 in a single day. These advances have allowed the generation of huge volumes of high‐quality human sequence data used to construct increasingly large catalogs of both population‐level and disease‐causing variation. The existence of such databases, coupled with a high‐quality human reference genome, means we are able to interrogate and annotate all types of genetic variation and identify pathogenic variants for many diseases. Increasingly, sequencing‐based approaches are being used to elucidate the underlying genetic cause of autoimmune diseases, a group of roughly 80 polygenic diseases characterized by abnormal immune responses where healthy tissue is attacked. Although sequence data generation has become routine and affordable, significant challenges remain with no gold‐standard methodology to identify pathogenic variants currently available. This review examines the latest methodologies used to identify pathogenic variants in autoimmune diseases and considers available sequencing options and subsequent bioinformatic methodologies and strategies. The development of reliable and robust sequencing and analytic workflows to detect pathogenic variants is critical to realize the potential of precision medicine programs where patient variant information is used to inform clinical practice. |
format | Online Article Text |
id | pubmed-7891608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78916082021-03-02 Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing Field, Matt A Immunol Cell Biol SPECIAL FEATURE: Omics in Immunology Sequencing the first human genome in 2003 took 15 years and cost $2.7 billion. Advances in sequencing technologies have since decreased costs to the point where it is now feasible to resequence a whole human genome for $1000 in a single day. These advances have allowed the generation of huge volumes of high‐quality human sequence data used to construct increasingly large catalogs of both population‐level and disease‐causing variation. The existence of such databases, coupled with a high‐quality human reference genome, means we are able to interrogate and annotate all types of genetic variation and identify pathogenic variants for many diseases. Increasingly, sequencing‐based approaches are being used to elucidate the underlying genetic cause of autoimmune diseases, a group of roughly 80 polygenic diseases characterized by abnormal immune responses where healthy tissue is attacked. Although sequence data generation has become routine and affordable, significant challenges remain with no gold‐standard methodology to identify pathogenic variants currently available. This review examines the latest methodologies used to identify pathogenic variants in autoimmune diseases and considers available sequencing options and subsequent bioinformatic methodologies and strategies. The development of reliable and robust sequencing and analytic workflows to detect pathogenic variants is critical to realize the potential of precision medicine programs where patient variant information is used to inform clinical practice. John Wiley and Sons Inc. 2020-07-27 2021-02 /pmc/articles/PMC7891608/ /pubmed/32623783 http://dx.doi.org/10.1111/imcb.12372 Text en © 2020 The Authors. Immunology & Cell Biology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | SPECIAL FEATURE: Omics in Immunology Field, Matt A Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing |
title | Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing |
title_full | Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing |
title_fullStr | Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing |
title_full_unstemmed | Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing |
title_short | Detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing |
title_sort | detecting pathogenic variants in autoimmune diseases using high‐throughput sequencing |
topic | SPECIAL FEATURE: Omics in Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891608/ https://www.ncbi.nlm.nih.gov/pubmed/32623783 http://dx.doi.org/10.1111/imcb.12372 |
work_keys_str_mv | AT fieldmatta detectingpathogenicvariantsinautoimmunediseasesusinghighthroughputsequencing |